To study the effect of salbutamol for treating pregnant women with red degeneration of uterine fibroids during pregnancy on their levels of serum insulin-like growth factor 1 (IGF-1), angiopoietin 2 (ANG-2) and their delivery outcomes. Methods: 87 pregnant women with red degeneration of uterine fibroids during pregnancy were selected and divided into observation group (n=44) and control group (n=43) by random number table method from January 2019 to January 2020. The women in the control group were treated with magnesium sulfate and the women in the observation group with salbutamol. Clinical efficacy, serum IGF-1 and Ang-2 levels, perinatal clinical indicators, delivery outcomes, and the incidence of adverse reactions of the women were compared between the two groups. Results: After treatment, the total effective rate (90.9%) of the women in the observation group was significant was higher than that (74.4%) of the women in the control group (P＜0.05). Serum IGF-1 and Ang-2 levels of the women in two groups had decreased with the treatment time significantly, and which of the women in the observation group was significant lower than those of the women in the control group. The time of body temperature recovery, time of lochia disappeared, disappearance of uterus contractions and postpartum abdominal pain of the women in the observation group were significant lower than those of the women in the control group (P＜0.05). The rate of adverse pregnancy outcomes (9.1%) of the women in the observation group was significant lower than that (30.2%) of the women in the control group, and the total incidence of adverse reactions (9.1%) of the women in the observation group was significant lower than that (27.9%) of the women in the control group (all P＜0.05). Conclusion: Salbutamol for treating pregnant women with red degeneration of uterine fibroids during pregnancy has good effectiveness, which can effectively decrease serum IGF-1 and Ang-2 levels with better safety.